FDA Approves NEXIUM(R) I.V. (Esomeprazole Sodium) For The Treatment Of GERD With Erosive Esophagitis In Pediatric And Adolescent Patients

Friday, Dec. 30th 2011 6:40 AM

AstraZeneca (NYSE: AZN) announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM® I.V. (esomeprazole sodium) for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not possible or appropriate.1 NEXIUM I.V.

VN:F [1.9.22_1171]
Rating: 4.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
FDA Approves NEXIUM(R) I.V. (Esomeprazole Sodium) For The Treatment Of GERD With Erosive Esophagitis In Pediatric And Adolescent Patients, 4.0 out of 5 based on 1 rating
Posted on Friday, Dec. 30th 2011 6:40 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply